If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCoca-Cola HBC Regulatory News (CCH)

Share Price Information for Coca-Cola HBC (CCH)

Share Price is delayed by 15 minutes
Get Live Data
5,105.00    80.00 (1.59%)
Bid:
5,100.00
Ask:
5,105.00
Spread: 5.00 (0.098%)
Market Cap: £18.61b
CCH Live PriceLast checked at - London Stock Exchange

Intraday Coca-Cola HBC Share Chart

Bitesize Investor series – Egypt

Today 07:00

RNS Number : 2106L
Coca-Cola HBC AG
07 July 2026
 

Coca-Cola HBC AG

Bitesize Investor series - Egypt

 

Zug, Switzerland - 07 July 2026 - Coca-Cola HBC AG ("Coca-Cola HBC", "Company", "we'), a growth-focused Consumer Packaged Goods business and strategic bottling partner of The Coca-Cola Company, is today holding the next event in its Bitesize Investor series in Cairo, Egypt.

Launched in 2024, Coca-Cola HBC's Bitesize Investor series showcases areas of the business that are important drivers of the Company's strategy and investment case.

Today's event focuses on our Egypt business, covering the attractive market landscape, the actions we have taken to integrate and strengthen the business following the acquisition in 2022, and the long-term growth opportunities ahead.

The session is intended to be educational in nature, and no new material financial information will be provided.

Details of the event are below:

Date: Tuesday 07 July 2026

Time: 08:30 - 11:00 CET

The event is hybrid, and the presentation and Q&A session with Coca-Cola HBC's management team and members of the Egypt leadership team will be available to watch via a live webcast here.

The presentation will be available shortly before 08:30 CET. A replay of the webinar will be available after the event on the Company's website.

Next event

05 August 2026 2026 Half-year results

Enquiries 

Coca‑Cola HBC Group

Investor and Analysts:

 

Jemima Benstead

Head of Investor Relations

Tel: +44 (0) 7740 535130

jemima.benstead@cchellenic.com

Elias Davvetas

Investor Relations Manager

Tel: +30 (694) 7568826

elias.davvetas@cchellenic.com

Matilde Durazzano

Investor Relations Manager

Tel: +44 (0) 7861 105884

matilde.durazzano@cchellenic.com

 

Elizabeth King

Investor Relations Manager

Tel: +44 (0) 7864 686582

elizabeth.king@cchellenic.com

 

Media:

Claire Evans

Head of Corporate Communications

 

Tel: +44 (0) 7896 054972

claire.evans@cchellenic.com

 

 

 

About Coca‑Cola HBC

Coca-Cola HBC is a growth-focused consumer packaged goods business and strategic bottling partner of

The Coca-Cola Company. We open up moments that refresh us all, by creating value for our stakeholders and supporting the socio-economic development of the communities in which we operate. With a vision to be the leading 24/7 beverage partner, we offer drinks for all occasions around the clock and work together with our customers to serve 760 million consumers across a broad geographic footprint of 29 countries. Our portfolio is one of the strongest, broadest and most flexible in the beverage industry, with consumer-leading brands across the sparkling, adult sparkling, juice, water, sport, energy, ready-to-drink tea, coffee, and premium spirits categories, with snacks as an additional offering. Our products include Coca-Cola, Coca-Cola Zero Sugar, Fanta, Sprite, Schweppes, Kinley, Costa Coffee, Caffè Vergnano, Valser, FuzeTea, Powerade, Cappy, Monster Energy, Finlandia Vodka, The Macallan, Jack Daniel's and Plazma. We foster an open and inclusive work environment for our more than 33,500 employees and believe that a positive environmental impact is integral to our future growth. We are among the leaders of the global beverage industry across major sustainability benchmarks, including the Dow Jones Best-in-Class Indices, CDP, MSCI ESG, FTSE ESG and ISS ESG.

 

Coca-Cola HBC is listed on the London Stock Exchange (LSE: CCH) and on Euronext Athens (Euronext Athens: EEE). For more information, please visit https://www.coca-colahellenic.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUPUUAMUPQGCQ
Date   Source Headline
7th Jul 20267:00 amRNSBitesize Investor series – Egypt
2nd Jul 202612:20 pmRNSDirector Declaration
30th Jun 20262:45 pmRNSDirector/PDMR Shareholding
29th Jun 202612:45 pmRNSDirector/PDMR Shareholding
26th Jun 20269:15 amRNSDirector/PDMR Shareholding
26th Jun 20269:15 amRNSDirector/PDMR Shareholding
18th Jun 20263:15 pmRNSDirector/PDMR Shareholding
15th Jun 20265:00 pmRNSDirector/PDMR Shareholding
22nd May 20263:30 pmRNSDirector/PDMR Shareholding
19th May 20263:15 pmRNSDirector/PDMR Shareholding
11th May 20269:00 amRNSDirector Declaration
8th May 20263:15 pmRNSComposition of the Board Committees
8th May 20263:10 pmRNSResult of AGM
7th May 20267:00 amRNSStrong volume drives Q1 sales growth
20th Apr 20263:15 pmRNSDirector/PDMR Shareholding
14th Apr 202612:15 pmRNSNotice of Results
2nd Apr 20267:00 amRNSNotice of AGM, changes to the BoD, dividend dates
1st Apr 20269:15 amRNSTransfer of treasury shares & total voting rights
31st Mar 202611:00 amRNSPublication of Final Terms
27th Mar 20262:45 pmRNSDirector/PDMR Shareholding
27th Mar 20262:15 pmRNSDirector/PDMR Shareholding
26th Mar 20266:18 pmRNSPricing of Issue of Notes
26th Mar 20269:05 amRNSLaunch of Issue of Notes
25th Mar 20261:36 pmRNSPublication of a Prospectus
20th Mar 202611:00 amRNSAnnual Financial Report
19th Mar 20264:55 pmRNSDirector/PDMR Shareholding
19th Mar 20264:45 pmRNSDirector/PDMR Shareholding
18th Mar 20264:15 pmRNSDirector/PDMR Shareholding
18th Mar 202611:35 amRNSDirector/PDMR Shareholding
26th Feb 202611:30 amRNSDirector/PDMR Shareholding
25th Feb 20269:20 amRNSDirector/PDMR Shareholding
24th Feb 20264:55 pmRNSDirector/PDMR Shareholding
24th Feb 20264:50 pmRNSDirector/PDMR Shareholding
23rd Feb 20264:40 pmRNSDirector/PDMR Shareholding
23rd Feb 20264:35 pmRNSDirector/PDMR Shareholding
18th Feb 20264:50 pmRNSDirector/PDMR Shareholding
18th Feb 20264:45 pmRNSDirector/PDMR Shareholding
18th Feb 20264:00 pmRNSDirector/PDMR Shareholding
17th Feb 20263:35 pmRNSDirector/PDMR Shareholding
17th Feb 20263:30 pmRNSDirector/PDMR Shareholding
16th Feb 20262:40 pmRNSDirector/PDMR Shareholding
16th Feb 20262:35 pmRNSDirector/PDMR Shareholding
13th Feb 202610:30 amRNSDirector/PDMR Shareholding
12th Feb 20263:45 pmRNSDirector/PDMR Shareholding
12th Feb 20261:15 pmRNSDirector/PDMR Shareholding
10th Feb 20267:00 amRNSStrong execution and financial performance in 2025
2nd Feb 202610:00 amRNSTransfer of treasury shares & total voting rights
19th Jan 20264:00 pmRNSDirector/PDMR Shareholding
19th Jan 20262:20 pmRNSResult of Extraordinary General Meeting
13th Jan 202611:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.